The presentation of brain metastases by breast cancer subtype and potential implications for surveillance brain MRIs

Current National Comprehensive Cancer Network (NCCN) Guidelines do not recommend routine brain MRI surveillance in breast cancer (BC) unless suspicious central nervous system (CNS) signs or symptoms are present. We sought to understand the presentation and outcomes of breast cancer brain metastasis (BM) by subtype to understand which patients are at sufficient risk to warrant brain MRI surveillance. Patients with BC who developed BM at our institution between 2015 and 2025 were identified. Details of demographics, initial presentation, treatments delivered, and overall survival (OS) were assessed. Kruskal–Wallis and Pearson’s chi-square tests were used to test differences between subtypes. OS was calculated from dates of initial BM diagnosis using the Kaplan–Meier (KM) method. The Cox proportional hazards model was used for multivariable analysis (MVA) to identify variables prognostic for OS. A total of 426 patients were identified including 176 (41%) hormone receptor (HR)+/HER2−, 133 (31%) HER2+, and 117 (28%) triple negative (TN). Patients with TN and HER2 + disease had shorter intervals from stage IV diagnosis to BM diagnosis (TN median:10.4 months, HER2 + : 12.6 months, and HR+/HER2-: 16 months, p = 0.006) and from initial BC diagnosis to BM diagnosis (TN median: 26.8 months, HER2 + : 27.8 months, and HR+/HER2−: 54.7 months, p < 0.0001). The median lines of therapy in the metastatic setting at BM diagnosis were HER2 + : 1, TN: 2, and HR+/HER2−: 3, p < 0.0001. Patients with TN disease were most likely to present without evidence of extracranial metastases (TN: 26%, HER2 + : 20%, and HR+/HER2− 13%, p = 0.02). Median KM OS following BM diagnosis was 38.1 months, 11.3, and 9.1 months, p < 0.0001, for HER2+, HR+/HER2−, and TN subtypes. On MVA, presence of leptomeningeal metastasis (LM) ( p = 0.0006), presence of ≥ 20 BM ( p = 0.002), > 2 lines of systemic therapy ( p < 0.0001), and symptomatic intracranial presentation ( p = 0.05) were significant for worse OS following BM diagnosis. Our institutional analysis found significant differences in the presentation of BM by breast cancer subtype with patients with TN and HER2 + disease presenting earlier in their diagnosis. Factors associated with shorter survival included ≥ 20 BMs, LM, and symptomatic BMs at presentation. These findings support the rationale for prospective evaluation of routine brain MRI surveillance in clinical trials to facilitate early detection in high-risk BC populations.

Authors

Institutions

Publication Details

Journal
Breast Cancer Research
Published
2026-11-18
DOI
https://doi.org/10.1186/s13058-026-02423-4
Primary Topic
Brain Metastases and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The presentation of brain metastases by breast cancer subtype and potential implications for surveillance brain MRIs

Jasmine A. Graham, Jennifer Barranco, Daniel Eli Oliver, Celina Chiodo et al.
2 links
Breast Cancer Research
Brain Metastases and Treatment
article

The presentation of brain metastases by breast cancer subtype and potential implications for surveillance brain MRIs

Jasmine A. Graham, Jennifer Barranco, Daniel Eli Oliver, Celina Chiodo, Aixa Elena Soyano, Rituraj Upadhyay, Rashmi Sarawagi, Vaseem M. Khatri, Matthew N. Mills, Kamran A. Ahmed, Hyo Sung Han, Yolanda Piña, Iman R Washington, Roberto Díaz, Peter Forsyth, Hatem H. Soliman, Hsiang-Hsuan Michael Yu
article en

Abstract

Current National Comprehensive Cancer Network (NCCN) Guidelines do not recommend routine brain MRI surveillance in breast cancer (BC) unless suspicious central nervous system (CNS) signs or symptoms are present. We sought to understand the presentation and outcomes of breast cancer brain metastasis (BM) by subtype to understand which patients are at sufficient risk to warrant brain MRI surveillance. Patients with BC who developed BM at our institution between 2015 and 2025 were identified. Details of demographics, initial presentation, treatments delivered, and overall survival (OS) were assessed. Kruskal–Wallis and Pearson’s chi-square tests were used to test differences between subtypes. OS was calculated from dates of initial BM diagnosis using the Kaplan–Meier (KM) method. The Cox proportional hazards model was used for multivariable analysis (MVA) to identify variables prognostic for OS. A total of 426 patients were identified including 176 (41%) hormone receptor (HR)+/HER2−, 133 (31%) HER2+, and 117 (28%) triple negative (TN). Patients with TN and HER2 + disease had shorter intervals from stage IV diagnosis to BM diagnosis (TN median:10.4 months, HER2 + : 12.6 months, and HR+/HER2-: 16 months, p = 0.006) and from initial BC diagnosis to BM diagnosis (TN median: 26.8 months, HER2 + : 27.8 months, and HR+/HER2−: 54.7 months, p < 0.0001). The median lines of therapy in the metastatic setting at BM diagnosis were HER2 + : 1, TN: 2, and HR+/HER2−: 3, p < 0.0001. Patients with TN disease were most likely to present without evidence of extracranial metastases (TN: 26%, HER2 + : 20%, and HR+/HER2− 13%, p = 0.02). Median KM OS following BM diagnosis was 38.1 months, 11.3, and 9.1 months, p < 0.0001, for HER2+, HR+/HER2−, and TN subtypes. On MVA, presence of leptomeningeal metastasis (LM) ( p = 0.0006), presence of ≥ 20 BM ( p = 0.002), > 2 lines of systemic therapy ( p < 0.0001), and symptomatic intracranial presentation ( p = 0.05) were significant for worse OS following BM diagnosis. Our institutional analysis found significant differences in the presentation of BM by breast cancer subtype with patients with TN and HER2 + disease presenting earlier in their diagnosis. Factors associated with shorter survival included ≥ 20 BMs, LM, and symptomatic BMs at presentation. These findings support the rationale for prospective evaluation of routine brain MRI surveillance in clinical trials to facilitate early detection in high-risk BC populations.

Breast Cancer Research
Moffitt Cancer Center (US)
Good health and well-being
Brain Metastases and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon